• 1
    Melton LJ III, Thamer M, Ray NF et al. Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:1623.
  • 2
    Melton LJ III, Lane AW, Cooper C et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:113119.
  • 3
    Chevalley T, Guilley E, Herrmann FR et al. Incidence of hip fracture over a 10-year period (1991–2000): Reversal of a secular trend. Bone 2007;40:12841289.
  • 4
    Autier P, Haentjens P, Bentin J et al. Costs induced by hip fractures: A prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 2000;11:373380.
  • 5
    Cauley JA, Thompson DE, Ensrud KC et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556561.
  • 6
    Kado DM, Browner WS, Palermo L et al. Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999;159:12151220.
  • 7
    Vestergaard P, Rejnmark L, Mosekilde L. Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int 2007;18:15831593.
  • 8
    Magaziner J, Lydick E, Hawkes W et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997;87:16301636.
  • 9
    Hannan EL, Magaziner J, Wang JJ et al. Mortality and locomotion 6 months after hospitalization for hip fracture: Risk factors and risk-adjusted hospital outcomes. JAMA 2001;285:27362742.
  • 10
    Van der Klift M, De Laet CE, McCloskey EV et al. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2002;17:10511056.
  • 11
    Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721739.
  • 12
    Berry SD, Samelson EJ, Hannan MT et al. Second hip fracture in older men and women: The Framingham Study. Arch Intern Med 2007;167:19711976.
  • 13
    Fox KM, Magaziner J, Hawkes WG et al. Loss of bone density and lean body mass after hip fracture. Osteoporos Int 2000;11:3135.
  • 14
    Colon-Emeric C, Kuchibhatla M, Pieper C et al. The contribution of hip fracture to risk of subsequent fractures: Data from two longitudinal studies. Osteoporos Int 2003;14:879883.
  • 15
    Gehlbach SH, Bigelow C, Heimisdottir M et al. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000;11:577582.
  • 16
    Simonelli C, Killeen K, Mehle S et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334338.
  • 17
    Gardner MJ, Brophy RH, Demetrakopoulos D et al. Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Jt Surg Am 2005;87:37.
  • 18
    Andrade SE, Majumdar SR, Chan KA et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:20522057.
  • 19
    Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922928.
  • 20
    Solomon DH, Finkelstein JS, Katz JN et al. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 2003;115:398400.
  • 21
    Penning-van Beest FJ, Erkens JA, Olson M et al. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008;24:13371344.
  • 22
    Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:14531460.
  • 23
    Lo JC, Pressman AR, Omar MA et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922928.
  • 24
    Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:10131022.
  • 25
    Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:18091822.
  • 26
    Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653661.
  • 27
    Black DM, Palermo L, Nevitt MC et al. Defining incident vertebral deformity: A prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:90101.
  • 28
    Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:17991809.
  • 29
    Lu Y, Fuerst T, Hui S et al. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 2001;12:438444.
  • 30
    Looker AC, Wahner HW, Dunn WL et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468489.
  • 31
    Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:8391.
  • 32
    Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:13441352.
  • 33
    McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333340.
  • 34
    Hochberg MC, Thompson DE, Black DM et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005;20:971976.
  • 35
    Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:18321839.
  • 36
    Caro JJ, Ishak KJ, Huybrechts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:10031008.
  • 37
    Papaioannou A, Kennedy CC, Dolovich L et al. Patient adherence to osteoporosis medications: Problems, consequences and management strategies. Drugs Aging 2007;24:3755.
  • 38
    van Eijken M, Tsang S, Wensing M et al. Interventions to improve medication compliance in older patients living in the community: Asystematic review of the literature. Drugs Aging 2003;20:229240.